Endometrical cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Pathologically confirmed endometrial cancer (Stage I–III, mainly endometrioid carcinoma, with a small amount of non-endometrioid carcinoma included); 2.Aged 18–75 years, ECOG performance status score 0–2; normal laboratory test results including liver and renal function and routine blood tests, with no contraindications to surgery or radiotherapy; 3.Assessed as intermediatehigh risk or above based on clinicopathological features and molecular classification, meeting the indications for postoperative adjuvant radiotherapy; 4.Voluntarily chose either transvaginal laparoscopic surgery (vNOTES) or transabdominal laparoscopic surgery (LPS) and achieved R0 resection; 5.Voluntarily signed the informed consent form and understood the study content, risks and benefits.
Exclusion criteria
Exclusion criteria: 1.Patients with FIGO stage IV disease, or with distant metastasis or lymph node metastasis. 2.Patients with a history of other malignant tumors, or with uncontrolled underlying diseases such as severe cardiovascular and cerebrovascular diseases or diabetes. 3.Patients who have previously received pelvic radiotherapy, chemotherapy, or hormone therapy. 4.Patients who did not achieve R0 resection, or who developed severe postoperative complications resulting in radiotherapy delay of more than 4 weeks. 5.Pregnant or lactating women; or patients with mental illness, cognitive impairment, who are unable to comply with the study and follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of grade >= 2 late toxicities at 3 years; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, OS;Progression-Free Survival, PFS;Acute toxicity incidence;Quality of Life (QoL) score; | — |
Countries
China
Contacts
Chengdu Women's and Children's Central Hospital